EZH2 Inhibition Enhances PD‐L1 Protein Stability Through USP22‐Mediated Deubiquitination in Colorectal Cancer (Adv. Sci. 23/2024)

Colon Cancer EZH2 inhibitor can activate the expression of deubiquitinase USP22 in colorectal cancer via canonical epigenetic regulation, thereby stabilizing PD-L1 protein and enhancing its expression, resulting in immune evasion and compromised anti-tumor efficacy. Combination with immunotherapy can overcome the immune suppressive effects of EZH2 inhibitors and achieve better outcome. More details can be found in article number 2308045 by Hao Wang, Jianling Yang, Lixiang Xue, and co-workers.